KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBT (2016 - 2025)

Historic EBT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.3 billion.

  • Vertex Pharmaceuticals' EBT rose 1711.39% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.6 billion, marking a year-over-year increase of 176849.09%. This contributed to the annual value of $4.6 billion for FY2025, which is 176849.09% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' EBT stood at $1.3 billion, which was up 1711.39% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EBT ranged from a high of $1.3 billion in Q4 2025 and a low of -$3.4 billion during Q2 2024
  • Over the past 5 years, Vertex Pharmaceuticals' median EBT value was $1.1 billion (recorded in 2021), while the average stood at $811.7 million.
  • In the last 5 years, Vertex Pharmaceuticals' EBT skyrocketed by 241764.71% in 2022 and then crashed by 39196.73% in 2024.
  • Vertex Pharmaceuticals' EBT (Quarter) stood at $870.9 million in 2021, then grew by 23.64% to $1.1 billion in 2022, then increased by 6.58% to $1.1 billion in 2023, then fell by 0.97% to $1.1 billion in 2024, then rose by 17.11% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.3 billion for Q3 2025, and $1.3 billion during Q2 2025.